AVXL

Anavex Life Sciences Corp.

4.99 USD
-0.09 (-1.77%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Anavex Life Sciences Corp. stock is down -24.39% since 30 days ago. The next earnings date is May 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
08 Jan 15:48 19 Jul, 2024 6.00 CALL 583 38
08 Jan 17:27 16 Feb, 2024 9.00 PUT 150 203
08 Jan 20:53 17 Jan, 2025 25.00 CALL 400 2690
10 Jan 18:59 19 Jul, 2024 6.00 CALL 178 621
11 Jan 18:06 19 Jan, 2024 9.50 PUT 100 304
26 Jan 16:03 17 Jan, 2025 8.00 PUT 92 2538
30 Jan 18:27 16 Jan, 2026 15.00 CALL 165 1048
07 Feb 16:37 16 Feb, 2024 8.00 PUT 120 149
07 Feb 20:36 17 Jan, 2025 5.00 CALL 144 473
16 Feb 20:01 16 Jan, 2026 7.00 CALL 100 53

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.